BRISTOL-MYERS SQUIBB CO (BMY) Stock Overview
USA - NYSE:BMY - US1101221083 - Common Stock
BMY Key Statistics, Chart & Performance
The current stock price of BMY is 44.39 USD. In the past month the price increased by 0.52%. In the past year, price decreased by -14.5%.
BMY Latest News, Press Relases and Analysis
BMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.31 | 768.93B | ||
| JNJ | JOHNSON & JOHNSON | 18.59 | 464.67B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.79 | 258.68B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.85 | 254.43B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.79 | 237.19B | ||
| MRK | MERCK & CO. INC. | 11.38 | 218.83B | ||
| PFE | PFIZER INC | 7.29 | 140.55B | ||
| SNY | SANOFI-ADR | 11.36 | 121.83B | ||
| GSK | GSK PLC-SPON ADR | 9.88 | 89.02B | ||
| ZTS | ZOETIS INC | 23.65 | 65.20B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.5 | 44.66B | ||
| HLN | HALEON PLC-ADR | 19.29 | 42.08B |
Related stock screener links
About BMY
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016 US
CEO: Giovanni Caforio
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What is the stock price of BRISTOL-MYERS SQUIBB CO today?
The current stock price of BMY is 44.39 USD. The price decreased by -0.34% in the last trading session.
What is the ticker symbol for BRISTOL-MYERS SQUIBB CO stock?
The exchange symbol of BRISTOL-MYERS SQUIBB CO is BMY and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BMY stock listed?
BMY stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for BRISTOL-MYERS SQUIBB CO stock?
33 analysts have analysed BMY and the average price target is 52.62 USD. This implies a price increase of 18.54% is expected in the next year compared to the current price of 44.39. Check the BRISTOL-MYERS SQUIBB CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BRISTOL-MYERS SQUIBB CO worth?
BRISTOL-MYERS SQUIBB CO (BMY) has a market capitalization of 90.35B USD. This makes BMY a Large Cap stock.
How many employees does BRISTOL-MYERS SQUIBB CO have?
BRISTOL-MYERS SQUIBB CO (BMY) currently has 34100 employees.
What are the support and resistance levels for BRISTOL-MYERS SQUIBB CO (BMY) stock?
BRISTOL-MYERS SQUIBB CO (BMY) has a support level at 43.91 and a resistance level at 45.57. Check the full technical report for a detailed analysis of BMY support and resistance levels.
Is BRISTOL-MYERS SQUIBB CO (BMY) expected to grow?
The Revenue of BRISTOL-MYERS SQUIBB CO (BMY) is expected to decline by -1.12% in the next year. Check the estimates tab for more information on the BMY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BRISTOL-MYERS SQUIBB CO (BMY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BMY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BMY, evaluating the profitability, health, valuation and growth aspects
- BRISTOL-MYERS SQUIBB CO (BMY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRISTOL-MYERS SQUIBB CO (BMY) Sales and EPS estimates to see what analysts future expectations are.
- BRISTOL-MYERS SQUIBB CO (BMY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRISTOL-MYERS SQUIBB CO (BMY) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRISTOL-MYERS SQUIBB CO (BMY) Stock Chart to make your own analysis
- BRISTOL-MYERS SQUIBB CO (BMY) Latest news and press-releases to stay up to date.
Does BRISTOL-MYERS SQUIBB CO (BMY) stock pay dividends?
BRISTOL-MYERS SQUIBB CO (BMY) has a dividend yield of 5.72%. The yearly dividend amount is currently 2.42. Check the full fundamental report for a detailed analysis of BMY dividend history, reliability and sustainability.
When does BRISTOL-MYERS SQUIBB CO (BMY) report earnings?
BRISTOL-MYERS SQUIBB CO (BMY) will report earnings on 2025-10-30, before the market open.
What is the Price/Earnings (PE) ratio of BRISTOL-MYERS SQUIBB CO (BMY)?
The PE ratio for BRISTOL-MYERS SQUIBB CO (BMY) is 6.6. This is based on the reported non-GAAP earnings per share of 6.73 and the current share price of 44.39 USD. Check the full fundamental report for a full analysis of the valuation metrics for BMY.
What is the Short Interest ratio of BRISTOL-MYERS SQUIBB CO (BMY) stock?
The outstanding short interest for BRISTOL-MYERS SQUIBB CO (BMY) is 1.45% of its float. Check the ownership tab for more information on the BMY short interest.
BMY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BMY. When comparing the yearly performance of all stocks, BMY is a bad performer in the overall market: 81.63% of all stocks are doing better.
BMY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BMY. While BMY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
BMY Financial Highlights
Over the last trailing twelve months BMY reported a non-GAAP Earnings per Share(EPS) of 6.73. The EPS increased by 391.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.58% | ||
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| Debt/Equity | 2.56 |
BMY Forecast & Estimates
33 analysts have analysed BMY and the average price target is 52.62 USD. This implies a price increase of 18.54% is expected in the next year compared to the current price of 44.39.
For the next year, analysts expect an EPS growth of 477.64% and a revenue growth -1.12% for BMY